Related Experiment Video
Updated: Jan 18, 2026
Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
Published on: February 14, 2021
Fecal calprotectin in patients with concomitant primary sclerosing cholangitis and inflammatory bowel disease: a
Giorgia Burrelli Scotti1, Fabrizio Zullo2, Marco Mattana1
1Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Background:
Primary sclerosing cholangitis (PSC) is strongly associated with inflammatory bowel disease (IBD), with up to 70% of PSC patients having concomitant IBD (PSC-IBD). Fecal Calprotectin (FC) is a validated surrogate biomarker of intestinal inflammation in IBD. Emerging evidence suggests that FC may also reflect biliary inflammation in PSC.
Aim:
This study aimed to compare FC concentrations in patients with PSC-IBD versus IBD only.
Methods:
A systematic literature search was performed (PROSPERO registration no. CRD42024600985). Studies reporting FC levels in both PSC-IBD and IBD-only patients were included. The outcome of interest was the difference in mean FC concentration between the two groups.
Results:
Seven studies met the inclusion criteria. There was no significant difference in the mean FC levels between PSC-IBD and IBD patients (-5.10, 95% confidence interval [CI] -45.40 to -35.2; p= 0.8). The findings remained non-significant when endoscopic remission was considered (12.82, 95% CI -19.33 to 44.97; p= 0.43).
Conclusions:
FC levels did not significantly differ between PSC-IBD and IBD groups. The available evidence is limited and heterogeneous. Larger, well-designed studies are needed to determine whether FC can serve as a surrogate biomarker of PSC progression, particularly in patients with endoscopic remission of colitis or without concomitant IBD.
Related Concept Videos
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:29Chronic Pancreatitis II: Collaborative Care
Assessment: